0000000000123658

AUTHOR

Marta Calvo

showing 2 related works from this author

Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study.

2017

Background: More than 50% of patients with Crohn's disease require intestinal resection at least once. Postoperative recurrence (POR) is almost uniform if prophylactic treatment is not started early. Endoscopic monitoring is generally advised. We studied the incidence and management of recurrence in patients who had undergone intestinal resection. Methods: Practicrohn was an observational retrospective study performed in 26 Spanish hospitals including patients aged >= 18 years who underwent Crohn's disease-related ileocolonic resection between January 2007 and December 2010. We recorded preventive treatments, the incidence of clinical recurrence in daily practice, and associated risk factor…

intestinal resectionAdultMaleReoperationmedicine.medical_specialtymedicine.medical_treatment03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseInterquartile rangeRecurrenceRisk FactorsSecondary Preventionpostoperative recurrenceImmunology and AllergyMedicineHumansImmunologic FactorsPostoperative PeriodColectomyColectomyRetrospective StudiesCrohn's diseasemedicine.diagnostic_testbusiness.industryIncidence (epidemiology)IncidenceGastroenterologyRetrospective cohort studyEndoscopyBowel resectionmedicine.diseaseSurvival AnalysisEndoscopySurgeryCrohn's diseaseLogistic ModelsSpain030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologyFemaleprophylaxisbusinessFollow-Up StudiesInflammatory bowel diseases
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct